Kevin advises clients on a range of commercialization strategies including supply chain and new drug launches.

He has a deep expertise in commercialization, operations, strategy and execution.

Prior to joining Avalere, Kevin led RxCrossroads by McKesson’s third-party logistics (3PL) business where he was responsible for breaking into a challenging market with long-established competition, developing a strategy to target small and midsized drug manufacturers to help commercialize their drug products, and creating value-based relationships to provide ongoing business development opportunities. Kevin had overall profit and loss responsibility and led the business from a startup within McKesson to an industry-recognized market leader with over 100 biopharma customers.

Before RxCrossroads, Kevin was responsible for the vaccine business within the McKesson Specialty Health division. Kevin designed the business growth strategy, developed marketing, education and sales incentive plans, and built and managed a cross functional leadership team of operations, account management, finance, human resources, and customer care members to enhance collaboration and align common objectives. Kevin also oversaw McKesson’s Centers for Disease Control and Prevention centralized distribution contract supporting the Vaccines for Children Program.

Prior to that, Kevin delivered SAP and special projects in support of new customer launches, new drug rollouts and distribution services. He sat on McKesson’s executive leadership team with overall responsibility for IT functions in support of the H1N1 pandemic response, which included warehousing and distributing over 125 million doses of H1N1 flu vaccine.

Kevin has a BS in economics from the University of Delaware

Authored Content

In this segment, our experts welcome leaders from Jazz Pharmaceuticals and Coherus BioSciences to discuss the selection process and key learnings and considerations for working with a third-party logistics (3PL) company.

The COVID-19 pandemic response has increased investment in vaccine innovations, but also exposed gaps in US and global vaccine access and delivery.

Manufacturers currently in the developmental phase for drug assets targeting rare or orphan diseases should assess the commercialization implications when bringing novel therapies to market and how they may differ from the standard pharmaceutical supply chain and economics.

Immunization Information Systems (IIS), or immunization registries, are used across the US to provide consolidated and complete accounts of patient immunization history in a given city, state, or region.

On January 21, the Biden administration released its National Strategy for the COVID-19 Response and Pandemic Preparedness. The plan highlights numerous actions that the administration intends to implement as it assumes responsibility in the fight against COVID-19.